JP2015038155A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015038155A5 JP2015038155A5 JP2014237466A JP2014237466A JP2015038155A5 JP 2015038155 A5 JP2015038155 A5 JP 2015038155A5 JP 2014237466 A JP2014237466 A JP 2014237466A JP 2014237466 A JP2014237466 A JP 2014237466A JP 2015038155 A5 JP2015038155 A5 JP 2015038155A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- beclomethasone
- effective amount
- monopropionate
- active corticosteroid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 12
- 239000003246 corticosteroid Substances 0.000 claims 8
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims 5
- 229950000210 beclometasone dipropionate Drugs 0.000 claims 5
- 238000002512 chemotherapy Methods 0.000 claims 4
- 239000002207 metabolite Substances 0.000 claims 4
- 102000003972 Fibroblast growth factor 7 Human genes 0.000 claims 3
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 claims 3
- OHYGPBKGZGRQKT-XGQKBEPLSA-N [(8s,9r,10s,11s,13s,14s,16s,17r)-9-chloro-11-hydroxy-17-(2-hydroxyacetyl)-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl] propanoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(OC(=O)CC)[C@@]1(C)C[C@@H]2O OHYGPBKGZGRQKT-XGQKBEPLSA-N 0.000 claims 3
- 229940006003 beclomethasone 17-monopropionate Drugs 0.000 claims 3
- 239000006186 oral dosage form Substances 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- 238000001959 radiotherapy Methods 0.000 claims 3
- 230000000451 tissue damage Effects 0.000 claims 3
- 231100000827 tissue damage Toxicity 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- OPNPEZLXXKGRTA-XGQKBEPLSA-N [2-[(8s,9r,10s,11s,13s,14s,16s,17r)-9-chloro-11,17-dihydroxy-10,13,16-trimethyl-3-oxo-6,7,8,11,12,14,15,16-octahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethyl] propanoate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(O)[C@@]1(C)C[C@@H]2O OPNPEZLXXKGRTA-XGQKBEPLSA-N 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 230000006378 damage Effects 0.000 claims 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 claims 1
- WRGQSWVCFNIUNZ-GDCKJWNLSA-N 1-oleoyl-sn-glycerol 3-phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)COP(O)(O)=O WRGQSWVCFNIUNZ-GDCKJWNLSA-N 0.000 claims 1
- 229940093444 Cyclooxygenase 2 inhibitor Drugs 0.000 claims 1
- 102400000921 Gastrin Human genes 0.000 claims 1
- 108010052343 Gastrins Proteins 0.000 claims 1
- 101800001586 Ghrelin Proteins 0.000 claims 1
- 102400000442 Ghrelin-28 Human genes 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 102000004137 Lysophosphatidic Acid Receptors Human genes 0.000 claims 1
- 108090000642 Lysophosphatidic Acid Receptors Proteins 0.000 claims 1
- 108010016076 Octreotide Proteins 0.000 claims 1
- 102100022763 R-spondin-2 Human genes 0.000 claims 1
- 101710110295 R-spondin-2 Proteins 0.000 claims 1
- 102100022766 R-spondin-3 Human genes 0.000 claims 1
- 101710110310 R-spondin-3 Proteins 0.000 claims 1
- 102100022759 R-spondin-4 Human genes 0.000 claims 1
- 101710110307 R-spondin-4 Proteins 0.000 claims 1
- 102000005157 Somatostatin Human genes 0.000 claims 1
- 108010056088 Somatostatin Proteins 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000006708 antioxidants Nutrition 0.000 claims 1
- 229940092705 beclomethasone Drugs 0.000 claims 1
- NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 230000005779 cell damage Effects 0.000 claims 1
- 230000001413 cellular effect Effects 0.000 claims 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 230000003013 cytotoxicity Effects 0.000 claims 1
- 231100000135 cytotoxicity Toxicity 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 210000002919 epithelial cell Anatomy 0.000 claims 1
- 210000000981 epithelium Anatomy 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- GNKDKYIHGQKHHM-RJKLHVOGSA-N ghrelin Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)CN)COC(=O)CCCCCCC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C1=CC=CC=C1 GNKDKYIHGQKHHM-RJKLHVOGSA-N 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 claims 1
- 229910052808 lithium carbonate Inorganic materials 0.000 claims 1
- 210000003750 lower gastrointestinal tract Anatomy 0.000 claims 1
- 229960002700 octreotide Drugs 0.000 claims 1
- 238000002360 preparation method Methods 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 claims 1
- 210000000813 small intestine Anatomy 0.000 claims 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims 1
- 229960000553 somatostatin Drugs 0.000 claims 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims 1
- 229960004291 sucralfate Drugs 0.000 claims 1
- 208000024891 symptom Diseases 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12078508P | 2008-12-08 | 2008-12-08 | |
| US61/120,785 | 2008-12-08 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011539796A Division JP5709266B2 (ja) | 2008-12-08 | 2009-12-08 | 放射線及び化学療法傷害に用いる局所的に活性なステロイド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015038155A JP2015038155A (ja) | 2015-02-26 |
| JP2015038155A5 true JP2015038155A5 (https=) | 2015-07-23 |
| JP5905562B2 JP5905562B2 (ja) | 2016-04-20 |
Family
ID=42310112
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011539796A Expired - Fee Related JP5709266B2 (ja) | 2008-12-08 | 2009-12-08 | 放射線及び化学療法傷害に用いる局所的に活性なステロイド |
| JP2014237466A Expired - Fee Related JP5905562B2 (ja) | 2008-12-08 | 2014-11-25 | 放射線及び化学療法傷害に用いる局所的に活性なステロイド |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011539796A Expired - Fee Related JP5709266B2 (ja) | 2008-12-08 | 2009-12-08 | 放射線及び化学療法傷害に用いる局所的に活性なステロイド |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20100183749A1 (https=) |
| EP (2) | EP2902031B1 (https=) |
| JP (2) | JP5709266B2 (https=) |
| KR (2) | KR101783577B1 (https=) |
| CN (2) | CN106692162A (https=) |
| AU (1) | AU2009333538B2 (https=) |
| CA (1) | CA2745930C (https=) |
| DK (2) | DK2902031T3 (https=) |
| IL (1) | IL213411A (https=) |
| NZ (1) | NZ593694A (https=) |
| SG (2) | SG10201704531XA (https=) |
| WO (1) | WO2010077681A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8889635B2 (en) | 2008-09-30 | 2014-11-18 | The Regents Of The University Of Michigan | Dendrimer conjugates |
| WO2010054321A2 (en) | 2008-11-07 | 2010-05-14 | The Regents Of The University Of Michigan | Methods of treating autoimmune disorders and/or inflammatory disorders |
| US9752124B2 (en) | 2009-02-03 | 2017-09-05 | Koninklijke Nederlandse Akademie Van Wetenschappen | Culture medium for epithelial stem cells and organoids comprising the stem cells |
| ES2579909T3 (es) | 2009-02-03 | 2016-08-17 | Koninklijke Nederlandse Akademie Van Wetenschappen | Medio de cultivo para células madre epiteliales y organoides que comprenden dichas células madre |
| EP2412800A1 (en) | 2010-07-29 | 2012-02-01 | Koninklijke Nederlandse Akademie van Wetenschappen | Liver organoid, uses thereof and culture method for obtaining them |
| US8912323B2 (en) | 2009-10-30 | 2014-12-16 | The Regents Of The University Of Michigan | Multifunctional small molecules |
| WO2012112791A1 (en) * | 2011-02-16 | 2012-08-23 | Paloma Pharmaceuticals, Inc. | Radiation countermeasure agents |
| US9402911B2 (en) | 2011-12-08 | 2016-08-02 | The Regents Of The University Of Michigan | Multifunctional small molecules |
| US10722577B2 (en) * | 2012-05-25 | 2020-07-28 | Sloan Kettering Institute For Cancer Research | Methods for treating GI syndrome and graft versus host disease |
| WO2014025832A1 (en) * | 2012-08-06 | 2014-02-13 | University Of Southern California | Wnt modulators for the protection, mitigation and treatment of radiation injury |
| WO2014059068A1 (en) * | 2012-10-11 | 2014-04-17 | The Trustees Of The University Of Pennsylvania | Methods for the treatment and prevention of osteoporosis and bone-related disorders |
| WO2014134038A1 (en) * | 2013-02-28 | 2014-09-04 | The Regents Of The University Of Michigan | Compositions and methods relating to induction of intestinal stem cell homeogenesis and/or regeneration |
| US11311598B2 (en) | 2013-09-13 | 2022-04-26 | Soligenix, Inc. | Peptides and analogs for use in the treatment of oral mucositis |
| DK3044229T3 (da) * | 2013-09-13 | 2023-12-18 | Jackson Lee | Peptider til anvendelse i behandlingen af oral mucositis |
| US9439947B2 (en) | 2014-03-28 | 2016-09-13 | Albert Einstein College Of Medicine, Inc. | Therapy for radiation-induced lung injury |
| WO2016054458A1 (en) * | 2014-10-02 | 2016-04-07 | Cytosorbents Corporation | Use of gastroinstestinally administered porous enteron sorbent polymers to prevent or treat radiation induced mucositis, esophagitis, enteritis, colitis, and gastrointestinal acute radiation syndrome |
| WO2017011457A1 (en) * | 2015-07-12 | 2017-01-19 | The University Of Tennessee Research Foundation | Compositions and methods for protecting colonic epithelial barrier function |
| WO2017119988A2 (en) * | 2015-12-10 | 2017-07-13 | Memorial Sloan Kettering Cancer Center | Radioprotection by wnt activation |
| CN107753932A (zh) * | 2016-08-22 | 2018-03-06 | 中国辐射防护研究院 | Kgf在制备治疗或预防放射性肠炎药物中的用途 |
| GB201721615D0 (en) | 2017-12-21 | 2018-02-07 | Koninklijke Nederlandse Akademie Van Wetenschappen | Immune cell organoid co-cultures |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4661509A (en) * | 1982-09-28 | 1987-04-28 | Gordon Arnold Z | Methods for treating leukopenia |
| US5252333A (en) * | 1987-04-27 | 1993-10-12 | Scotia Holdings Plc | Lithium salt-containing pharmaceutical compositions |
| US6077692A (en) * | 1995-02-14 | 2000-06-20 | Human Genome Sciences, Inc. | Keratinocyte growth factor-2 |
| US20030144202A1 (en) * | 1996-10-15 | 2003-07-31 | Amgen Inc. | Uses of keratinocyte growth factor-2 |
| WO2001024812A1 (en) * | 1999-10-06 | 2001-04-12 | N.V. Nutricia | USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA |
| US20020086857A1 (en) * | 2000-09-15 | 2002-07-04 | Mcdonald George B. | Method of long-term treatment of graft-versus-host disease using topical active corticosterioids |
| US7544348B2 (en) * | 2001-02-15 | 2009-06-09 | Access Pharmaceuticals, Inc. | Liquid formulations for the prevention and treatment of mucosal diseases and disorders |
| WO2002074316A1 (en) * | 2001-03-15 | 2002-09-26 | Enteron Pharmaceuticals, Inc. | Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids |
| CA2583244A1 (en) * | 2004-12-30 | 2006-07-06 | Dor Biopharma, Inc. | Treatment of graft-versus-host disease and leukemia with beclomethasone dipropionate and prednisone |
| JP4839436B2 (ja) * | 2005-11-02 | 2011-12-21 | 国立大学法人徳島大学 | 消化管粘膜保護剤、カベオリン遺伝子発現促進剤及び抗ストレス剤 |
| US20070293458A1 (en) | 2006-06-16 | 2007-12-20 | Ip-6 Research Inc. | Prevention of nuclear, solar, and other radiation-induced tissue damage |
| WO2008101215A1 (en) * | 2007-02-16 | 2008-08-21 | Varian Medical Systems Technologies, Inc. | Preparative regimen for engraftment, growth and differentiation of non-hematopoeitic cells in vivo |
| EP2214679B1 (en) * | 2007-11-13 | 2019-03-27 | Meritage Pharma, Inc. | Corticosteroid compositions |
-
2009
- 2009-12-08 KR KR1020167036277A patent/KR101783577B1/ko not_active Expired - Fee Related
- 2009-12-08 KR KR1020117015534A patent/KR20110092351A/ko not_active Ceased
- 2009-12-08 EP EP15158919.9A patent/EP2902031B1/en not_active Not-in-force
- 2009-12-08 SG SG10201704531XA patent/SG10201704531XA/en unknown
- 2009-12-08 AU AU2009333538A patent/AU2009333538B2/en not_active Ceased
- 2009-12-08 NZ NZ593694A patent/NZ593694A/xx not_active IP Right Cessation
- 2009-12-08 CA CA2745930A patent/CA2745930C/en active Active
- 2009-12-08 DK DK15158919.9T patent/DK2902031T3/en active
- 2009-12-08 JP JP2011539796A patent/JP5709266B2/ja not_active Expired - Fee Related
- 2009-12-08 SG SG2011041332A patent/SG171997A1/en unknown
- 2009-12-08 WO PCT/US2009/067199 patent/WO2010077681A1/en not_active Ceased
- 2009-12-08 CN CN201710119024.2A patent/CN106692162A/zh active Pending
- 2009-12-08 EP EP09836727.9A patent/EP2373160B1/en not_active Not-in-force
- 2009-12-08 DK DK09836727.9T patent/DK2373160T3/en active
- 2009-12-08 US US12/633,631 patent/US20100183749A1/en not_active Abandoned
- 2009-12-08 CN CN2009801562821A patent/CN102307466A/zh active Pending
-
2011
- 2011-06-06 IL IL213411A patent/IL213411A/en active IP Right Grant
-
2014
- 2014-11-25 JP JP2014237466A patent/JP5905562B2/ja not_active Expired - Fee Related
-
2017
- 2017-04-24 US US15/495,798 patent/US20170333448A1/en not_active Abandoned
-
2019
- 2019-06-21 US US16/448,526 patent/US20200155571A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015038155A5 (https=) | ||
| JP2012511034A5 (https=) | ||
| CA3004028C (en) | Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives | |
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| CN114641293A (zh) | 一种fgfr抑制剂的用途 | |
| CY1122626T1 (el) | Κορτικοστεροειδες που περιεχει τις συνθεσεις των δισκιων που διασπωνται απο το στομα για την ηωσινοφιλικη οισοφαγιτιδα | |
| US20240058353A1 (en) | Methods for treating gi tract disorders | |
| JP2015038135A5 (https=) | ||
| JP2014526503A5 (https=) | ||
| JP2014528901A5 (https=) | ||
| ME02474B (me) | Terapijski režimi | |
| JP2020503269A5 (https=) | ||
| RU2015126661A (ru) | Пероральная комбинация для предотвращения и лечения патологий мочевого пузыря, органов малого таза и мочеполового аппарата | |
| JP2015516418A5 (https=) | ||
| JP2019530706A5 (https=) | ||
| JP2020500864A5 (https=) | ||
| JP2018516266A (ja) | 疼痛治療のためのセレコキシブの経口用組成物 | |
| FI3706724T3 (fi) | Suun kautta otettavia rifamysiini sv -koostumuksia | |
| RU2015137612A (ru) | Фармацевтическая дозированная лекарственная форма в виде мягкой желатиновой капсулы, содержащая модифицированную гуаровую камедь | |
| WO2011083402A3 (en) | Immediate release compositions of acid labile drugs | |
| ES2829285T3 (es) | Administración de AINE y composiciones, métodos y sistemas relacionados | |
| JP2019509309A5 (https=) | ||
| JP2012041314A5 (https=) | ||
| US20170165280A1 (en) | Pharmaceutical formulations for treating skin disorders and methods for fabricating and using thereof | |
| WO2021003279A1 (en) | System for enhancing therapeutic compliance of the anti-cancer compound e7766 |